polycythaemia vera

News

Merck buys Silence and its siRNA pipeline for $1.3bn

Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

Lilly's M&A team strikes again with $2.3bn Ajax takeover

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

Merck buys Silence and its siRNA pipeline for $1.3bn

FDA clears Takeda, Protagonist's first-in-class PV drug

Lilly's M&A team strikes again with $2.3bn Ajax takeover

Takeda scores with polycythemia vera drug in phase 3 trial

Takeda grabs late-stage haematology drug from Protagonist

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

polycythaemia vera

Editor's Picks